On August 21, DUALITYBIO-B rose 5.22% in regular trading, trading at HKD 197.5/share, with turnover of HKD 48.06 million.

On the news front, UBS recently initiated coverage on DUALITYBIO-B with a Buy rating and a target price of HKD 320, implying approximately 62% upside from the current share price. UBS noted the stock trades at only 0.7x risk-adjusted peak sales ratio, well below the peer median of 1.6x, and projects DB-1311 peak sales of RMB 38.3 billion, above market consensus of RMB 28.6 billion. Additionally, China Merchants Securities, Soochow Securities, and China Galaxy Securities have each initiated coverage with positive ratings in recent weeks.

Meanwhile, the company is scheduled to release its interim results on August 28, covering the six months ended June 30. Combined with continuous share buybacks since May — including repurchases on June 5, June 10, June 16, and June 26 — institutional bullish sentiment and earnings release expectations are forming a positive resonance for the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)